Seres Therapeutics price to free cash flow MCRB

Market value divided by free cash flow over the last twelve months, since 2016.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 84.3×; May 2026
10-year median: 20.3×
10-year range: 10.2× to 103×
Peer median: 11.0×

Seres Therapeutics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in May 2026, at 84.3×.

On the days it had one over the last ten years, its median was 20.3×, from 10.2× in Feb 2017 to 103× in Apr 2026.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	84.3×	84.3×	103×
2025	n/m a value too high to mean anything
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	23.4×	20.9×	24.2×
2021	23.6×	21.9×	30.3×
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	17.7×	10.2×	21.7×
2016	11.1×	6.2×	22.2×

Against its peers

Companies in Drug Manufacturers - General nearest Seres Therapeutics' size, closest first, today.

Company	Price to free cash flow
MCRBSeres Therapeutics	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	n/m
LFVNLifevantage	11.0×
Peer median	11.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Seres Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.